ipratropium + fenoterol


Boehringer Ingelheim


Concise Prescribing Info
Per 4 mL Ipratropium Br 0.5 mg, fenoterol HBr 1.25 mg
Bronchodilator for the prevention & treatment of symptoms in chronic obstructive airway disorders w/ reversible airflow limitation eg, bronchial asthma & especially chronic bronchitis w/ or w/o emphysema. Concomitant anti-inflammatory therapy considered for patients w/ bronchial asthma & steroid-responsive COPD.
Dosage/Direction for Use
Adult (including elderly) & adolescent >12 yr Acute bronchospasm episodes 1 unit-dose vial. Very severe cases 2 unit-dose vials may be required for symptom relief.
Hypersensitivity to fenoterol HBr or atropine-like substances. Patients w/ hypertrophic obstructive cardiomyopathy & tachyarrhythmia.
Special Precautions
Immediate hypersensitivity reactions may occur. Discontinue immediately & substitute alternative therapy if paradoxical bronchospasm occurs. Patients predisposed to narrow-angle glaucoma. When using higher doses than recommended, carefully assess risk/benefit in patients w/ insufficiently controlled DM, recent MI, severe organic heart or vascular disorders, hyperthyroidism, phaeochromocytoma, or w/ pre-existing urinary outflow tract obstruction (eg, prostatic hyperplasia or bladder-neck obstruction). Patients w/ underlying severe heart disease (eg, ischaemic heart disease, arrhythmia or severe heart failure). Potentially serious hypokalaemia. Patients w/ cystic fibrosis may be more prone to GI motility disturbances. Immediately consult a physician in case of acute, rapidly worsening dyspnoea. Prolonged use. Concomitant use w/ other sympathomimetic bronchodilators. May lead to positive results (w/ regard to fenoterol) in tests for non-clinical substance abuse eg, athletic performance enhancement (doping). Dizziness, tremor, accommodation disorder, mydriasis & blurred vision during treatment may affect ability to drive or use machines. Pregnancy (especially 1st trimester) & lactation. Not recommended in childn ≤12 yr.
Adverse Reactions
Cough, dry mouth, headache, tremor, pharyngitis, nausea, dizziness, dysphonia, tachycardia, palpitations, vomiting, increased systolic BP & nervousness.
Drug Interactions
Chronic co-administration w/ other anticholinergics is not recommended. May enhance bronchodilatatory effect w/ other β-adrenergics, anticholinergics & xanthine derivatives (eg, theophylline). Potentially serious reduction in bronchodilatation w/ β-blockers. Induced hypokalaemia w/ xanthine derivatives, corticosteroids & diuretics. May increase susceptibility to arrhythmias w/ digoxin. May enhance action by MAOIs, TCAs. May increase susceptibility on CV effects w/ halogenated hydrocarbon anaesth inhalation (eg, halothane, trichloroethylene & enflurane).
ATC Classification
R03AL01 - fenoterol and ipratropium bromide ; Belongs to the class of combination of adrenergics with anticholinergics, that may also include a corticosteroid. Used in the treatment of obstructive airway diseases.
Duovent nebuliser soln
(unit-dose) 4 mL x 60 × 1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in